Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study.

ABSTRACT:

Background

Cabozantinib is a tyrosine kinase inhibitor with a substantial efficacy in metastatic renal cell carcinoma, and is associated with a challenging toxicity profile leading to frequent drug discontinuations. Whereas an exposure/safety relationship was demonstrated for this drug, an exposure/efficacy relationship is still unknown.

Patients and methods

We carried out a monocentric, observational, pharmacokinetics/pharmacodynamics (PK/PD) study in patients with metastatic renal cell carcinoma (INDS MR 5612140520). We used measured blood concentrations of cabozantinib (C_meas) to determine the area under the curve (AUC), apparent clearance (Cl/F) and residual blood concentration (C_trough). Best overall response according to RECIST 1.1 and relevant to

SUBMITTER: Cerbone L 

PROVIDER: S-EPMC8645912 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature